Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday.
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice's Federal Bureau of Investigation.
Dow Turns Higher; Crude Oil Rises Over 3%
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 80 points on Tuesday.
The Dow traded up 0.05% to 33,906.31 while the NASDAQ rose 0.69% to 11,969.79. The S&P 500 also rose, gaining, 0.40% to 4,127.37.
LIXTE Biotechnology Stock Jumps As Lead Program Shows Cancer Killing Activity In Animal Models
LIXTE Biotechnology Holdings Inc (NASDAQ:LIXT) noted that a team of scientists reported that in three difficult-to-treat cancer types, LIXTE’s…
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Lixte Biotech Hldgs (NASDAQ:LIXT) shares rose 97.3% to $1.6 during Tuesday’s regular session. Trading volume for this…
Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, LB-100, Can Kill Cancer Cells Through Hyper-Stimulation Of Cell Proliferation Signals In Pre-Clinical Models; Shares Halted On Circuit Breaker To The Upside
--THE STUDY ESTABLISHES A NOVEL CONCEPT OF "TUMOR SUPPRESSIVE DRUG RESISTANCE"
--THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE MODULATORS WAS HIGHLY EFFECTIVE IN
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Iterum Therapeutics (NASDAQ:ITRM) shares moved upwards by 8.5% to $1.28 during Friday’s after-market session. The company’s market…
Lixte Biotechnology Announces Approval Of A Phase 1B/2 Randomized Trial Of Doxorubicin +/-lb-100 In Advanced Soft Tissue Sarcomas To Be Conducted By The Spanish Sarcoma Group
LIXTE Biotechnology Holdings, Inc. (NASDAQ:LIXT), ("LIXTE" or the "Company"), a clinical-stage pharmaceutical company focused on developing and commercializing cancer therapies, announced that
